Skip to contentE
ENDRA Life Sciences Inc.
E
NDRAENDRA Life Sciences Inc. Q1 2022 · 10-Q
Revenue—
Net Income-$2.86M-$2.86MN/M vs Q1 2021 EPS Diluted-$0.07-$0.07N/M vs Q1 2021 Operating Income-$2,855,269N/M Operating Cash Flow-$3,098,870N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ENDRA Life Sciences Inc. · CIK 1681682 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,188,223N/M ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end